Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
1158
mi
from
Costa Mesa, CA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
1158
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
1210
mi
from
Fresno, CA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
1210
mi
from
Fresno, CA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
1118
mi
from
La Jolla, CA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
1118
mi
from
La Jolla, CA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
1154
mi
from
Santa Ana, CA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
1154
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
1285
mi
from
Delray Beach, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
1285
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
1314
mi
from
Hialeah, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
1314
mi
from
Hialeah, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
1053
mi
from
Jacksonville, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
1053
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
1320
mi
from
Miami, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
1320
mi
from
Miami, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
1139
mi
from
Orlando, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
1139
mi
from
Orlando, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
1117
mi
from
Tampa, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
1117
mi
from
Tampa, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
1284
mi
from
W Palm Beach, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
1284
mi
from
W Palm Beach, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
637
mi
from
Baton Rouge, LA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
637
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
1301
mi
from
Cedarhurst, NY
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
1301
mi
from
Cedarhurst, NY
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
959
mi
from
Charlotte, NC
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
959
mi
from
Charlotte, NC
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
156
mi
from
Tulsa, OK
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
156
mi
from
Tulsa, OK
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
522
mi
from
Austin, TX
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
522
mi
from
Austin, TX
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
9338
mi
from
Adelaide,
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
9338
mi
from
Adelaide,
Click here to add this to my saved trials
Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)
Semantic Memory, Financial Capacity and Brain Perfusion in MCI
Status: Enrolling
Updated:  2/24/2016
Birmingham VA Medical Center, Birmingham, AL
684
mi
from
Birmingham, AL
Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)
Semantic Memory, Financial Capacity and Brain Perfusion in MCI
Status: Enrolling
Updated: 2/24/2016
Birmingham VA Medical Center, Birmingham, AL
684
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3202626
Status: Enrolling
Updated:  2/25/2016
California Clinical Trials Medical Group
1164
mi
from
Glendale, CA
A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3202626
Status: Enrolling
Updated: 2/25/2016
California Clinical Trials Medical Group
1164
mi
from
Glendale, CA
Click here to add this to my saved trials
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for AD: "Statins in Healthy, At-Risk Adults: Impact on Amyloid and Regional Perfusion (SHARP)" Study
Status: Enrolling
Updated:  2/26/2016
University of Wisconsin
574
mi
from
Madison, WI
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for AD: "Statins in Healthy, At-Risk Adults: Impact on Amyloid and Regional Perfusion (SHARP)" Study
Status: Enrolling
Updated: 2/26/2016
University of Wisconsin
574
mi
from
Madison, WI
Click here to add this to my saved trials
A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery
A Multi-Center Longitudinal Biorepository Study to Provide Biospecimens & Clinical Data From Neurological Disease Patients To Approved Pre-Clinical And Clinical Investigators for Drug & Biomarker Studies
Status: Enrolling
Updated:  3/1/2016
Sanguine Biosciences
1178
mi
from
Los Angeles, CA
A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery
A Multi-Center Longitudinal Biorepository Study to Provide Biospecimens & Clinical Data From Neurological Disease Patients To Approved Pre-Clinical And Clinical Investigators for Drug & Biomarker Studies
Status: Enrolling
Updated: 3/1/2016
Sanguine Biosciences
1178
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated:  3/2/2016
Naples Medical Center
1232
mi
from
Naples, FL
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated: 3/2/2016
Naples Medical Center
1232
mi
from
Naples, FL
Click here to add this to my saved trials
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated:  3/2/2016
University of Maryland
1148
mi
from
Baltimore, MD
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated: 3/2/2016
University of Maryland
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated:  3/2/2016
Primary Care Cardiology Research
1418
mi
from
Ayer, MA
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated: 3/2/2016
Primary Care Cardiology Research
1418
mi
from
Ayer, MA
Click here to add this to my saved trials
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated:  3/2/2016
Rivercourt Residences
1419
mi
from
Groton, MA
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated: 3/2/2016
Rivercourt Residences
1419
mi
from
Groton, MA
Click here to add this to my saved trials
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated:  3/2/2016
Mary Immaculate Residential
1440
mi
from
Lawrence, MA
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated: 3/2/2016
Mary Immaculate Residential
1440
mi
from
Lawrence, MA
Click here to add this to my saved trials
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated:  3/2/2016
D'Youville Senior Care
1430
mi
from
Lowell, MA
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated: 3/2/2016
D'Youville Senior Care
1430
mi
from
Lowell, MA
Click here to add this to my saved trials
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated:  3/2/2016
The NeuroCognitive Institute
1254
mi
from
Mt. Arlington, NJ
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated: 3/2/2016
The NeuroCognitive Institute
1254
mi
from
Mt. Arlington, NJ
Click here to add this to my saved trials
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated:  3/2/2016
Advanced Memory Dynamics
784
mi
from
Layton, UT
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated: 3/2/2016
Advanced Memory Dynamics
784
mi
from
Layton, UT
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Banner Alzheimer'S Institute
851
mi
from
Phoenix, AZ
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Banner Alzheimer'S Institute
851
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Banner Boswell Medical Center
859
mi
from
Sun City, AZ
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Banner Boswell Medical Center
859
mi
from
Sun City, AZ
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Banner Sun Health Research Institute
859
mi
from
Sun City, AZ
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Banner Sun Health Research Institute
859
mi
from
Sun City, AZ
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
University of California at San Francisco
1341
mi
from
San Francisco, CA
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
University of California at San Francisco
1341
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Yale-New Haven Hospital
1344
mi
from
New Haven, CT
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Yale-New Haven Hospital
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Yale University School of Medicine
1344
mi
from
New Haven, CT
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Yale University School of Medicine
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
General Clinical Research Unit
1124
mi
from
Washington,
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
General Clinical Research Unit
1124
mi
from
Washington,
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Georgetown University Medical Center
1127
mi
from
Washington,
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Georgetown University Medical Center
1127
mi
from
Washington,
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
MD Clinical
1313
mi
from
Hallandale Beach, FL
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
MD Clinical
1313
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Palm Beach Neurology and Premiere Research Institute
1284
mi
from
West Palm Beach, FL
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Palm Beach Neurology and Premiere Research Institute
1284
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Brigham and Woman's Hospital
1444
mi
from
Boston, MA
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Brigham and Woman's Hospital
1444
mi
from
Boston, MA
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Center for Alzheimer Research and Treatment
1444
mi
from
Boston, MA
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Center for Alzheimer Research and Treatment
1444
mi
from
Boston, MA
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Barnes Jewish Hospital
414
mi
from
St. Louis, MO
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Barnes Jewish Hospital
414
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Washington University School of Medicine
415
mi
from
St. Louis, MO
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Washington University School of Medicine
415
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Barnes Jewish Hospital - Washington University
414
mi
from
St. Louis, MO
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Barnes Jewish Hospital - Washington University
414
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Memory Enhancement Center of America, Inc.
1283
mi
from
Eatontown, NJ
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Memory Enhancement Center of America, Inc.
1283
mi
from
Eatontown, NJ
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Columbia University Taub Institute
1225
mi
from
New York, NY
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Columbia University Taub Institute
1225
mi
from
New York, NY
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
CUMC Research Pharmacy
1290
mi
from
New York, NY
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
CUMC Research Pharmacy
1290
mi
from
New York, NY
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Butler Hospital
1424
mi
from
Providence, RI
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Butler Hospital
1424
mi
from
Providence, RI
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Southwestern Vermont Healthcare
1339
mi
from
Bennington, VT
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Southwestern Vermont Healthcare
1339
mi
from
Bennington, VT
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
The Memory Clinic
1339
mi
from
Bennington, VT
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
The Memory Clinic
1339
mi
from
Bennington, VT
Click here to add this to my saved trials